Clinical trial
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Dotinurad Compared With Allopurinol in Adult Participants With Hyperuricemia Associated With Gout
NCT07089875 is registered in ClinicalTrials.gov with Crystalys Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Dotinurad Compared With Allopurinol in Adult Participants With Hyperuricemia Associated With Gout
- Lead sponsor
- Crystalys Therapeutics
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- August 1, 2025
- Completion date
- November 29, 2027
- Enrollment
- 500 (estimated)
- Sites
- 115
Conditions
As the registry lists them; a condition with its own page is linked.